Results 101 to 110 of about 2,103,376 (217)
The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński +12 more
wiley +1 more source
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis +20 more
wiley +1 more source
Lung cancer remains the leading cause of cancer-related mortality worldwide, emphasizing the critical need for novel and robust biomarkers to improve prognostication and guide precision oncology.
Stevens, Emmy +5 more
core +1 more source
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi +2 more
wiley +1 more source
Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts +15 more
wiley +1 more source
MicroRNAs as Biomarkers of Brain Tumor [PDF]
Wojciech Jelski,1 Barbara Mroczko1,2 1Department of Biochemical Diagnostics, Medical University, Bialystok, Poland; 2Department of Neurodegeneration Diagnostics, Medical University, Bialystok, PolandCorrespondence: Wojciech Jelski, Department of ...
Jelski W, Mroczko B
core
Emerging biomarkers for PD-1 pathway cancer therapy.
The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types.
Sundar, R +4 more
core +1 more source
Osimertinib is effective against EGFR‐mutant NSCLC, but resistance often develops. We found that increased cholesterol in lipid rafts, specialized regions of the cell membrane, promotes recruitment of the scaffold protein FLOT1 and insulin receptors.
Yen‐Lin Lai +2 more
wiley +1 more source
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová +2 more
wiley +1 more source

